Metabolic reprogramming drives radiotherapy resistance in glioblastoma and strategies for targeted therapy
10.3760/cma.j.cn113030-20241113-00434
- VernacularTitle:代谢重编程驱动胶质母细胞瘤放射抵抗及靶向治疗策略
- Author:
Zhaohui JIN
1
;
Liang LIU
;
Chunfa QIAN
;
Kun YANG
;
Mengjie ZHAO
Author Information
1. 南京医科大学附属脑科医院神经外科，南京 210029
- Publication Type:Journal Article
- Keywords:
Glioblastoma;
Metabolic reprogramming;
Radiotherapy resistance;
Targeted therapy
- From:
Chinese Journal of Radiation Oncology
2025;34(8):839-846
- CountryChina
- Language:Chinese
-
Abstract:
Glioblastoma (GBM) is the most aggressive malignant tumor of the adult central nervous system, with limited treatment options and poor prognosis. Radiotherapy (RT) remains a cornerstone of GBM treatment; however, tumor cell resistance to RT severely limits its efficacy. Recently, metabolic reprogramming (MR) has gained widespread attention as a critical mechanism enabling GBM cells to evade RT‐induced stress. In this review, the central roles of glucose, lipid, and amino acid metabolic reprogramming in GBM's resistance to RT were outlined, highlighting how GBM remodels metabolic pathways to enhance DNA damage repair, antioxidant defenses, and immune evasion after RT. Although combining metabolic inhibitors with RT has shown potential in improving GBM treatment outcomes, challenges such as overcoming the blood‐brain barrier and addressing tumor heterogeneity remain. The integration of nanomedicine‐based delivery systems and immunotherapy offers new hope for GBM treatment. Future research should focus on developing multidimensional, personalized metabolic targeting strategies, combined with immunotherapy and emerging technologies, to further improve therapeutic outcomes and survival rates for GBM patients.
